Canada Approves First Generic Ozempic, Raising Novo Nordisk's Competitive Risks

What happened

Canada became the first G7 country to approve a generic version of Novo Nordisk's Ozempic (semaglutide) from Dr. Reddy's Laboratories, marking an early breach of patent exclusivity in a major market. The approval threatens Novo's pricing power and market share in Canada, a key international region, and could set a precedent for other developed countries. This development comes as Novo already faces intense price competition from Eli Lilly's Zepbound and illicit compounding in the U.S., exacerbating near-term net-price erosion. The DeepValue report had flagged generic entry as a risk, but the timing—prior to key U.S. patent expirations—accelerates the threat.

Implication

Investors should weigh this event as a clear negative that reinforces the bear case in the DeepValue report. While Canada is a smaller market relative to the U.S., the precedent of a G7 nation approving a generic Ozempic could accelerate regulatory pathways elsewhere and intensify pricing headwinds. The thesis now faces an earlier-than-expected threat to exclusivity; re-assess position size if further generic approvals surface in other territories. The WAIT rating remains appropriate, but the attractive entry price may need to be revisited downward to $30 in the bear scenario.

Thesis delta

This news shifts the thesis toward the bear scenario, increasing the probability that net-price erosion accelerates as generic entry in Canada opens the door for broader competition. The prior base case relied on continued exclusivity in developed markets until at least 2027; Canada's approval introduces a tangible risk of earlier profit-pool compression. The key monitoring point now extends beyond U.S. share stabilization to include generic developments in other G7 countries.